Emre Karabay

Assoc. Prof. of Urology @AcibademSaglik, graduated from @cerrahpasatipf

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

En bloc TURBT (for <1 cm tumors) results in

Similar recurrence rates: 18.4% vs 16.7% at 1 yr

Similar residual disease on reTUR 56% vs 55.9% (small subset)

More retrieval of DM: 80.7% vs 71.1%

Less bladder perforation: 5.6% vs 12%

Similar OR time: 26 vs 25 min

#BladderCancer @IBCG_BladderCA @EurUrolOncol
@DrShariat @evacomperat @paolo_gontero @jteoh_hk @siadaneshmand @JoshMeeks

[Dmitry Enikeev @Dmitry_Enikeev]

Finally it’s online in @wjurol. Meta-analysis #AEEP vs #TURP long-term outcomes. https://t.co/LAlulRWwzx Naturally, all benefits go for #AEEP. Thanks for all the experts who were involved @AndreyOMorozov @jteoh_hk @JGomezRivas @lusuardi_lukas @A_Shpikina @trwherrmann

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Our collaborative review on LND in GU cancers; tremendous effort by @AmandaMyersMD @MDAndersonNews #OncSurgery @EurUrolOncol

Open Access link: https://t.co/3F4r1jjHz0

@Albert0Briganti @BradLeibovichMD #SethLerner @UroMoschini @MRoupret @DrShariat @SpiessPhilippe @Astenzl @Tanejauro @TouijerKarim

[Hikmet Pınarbaş @hikmetpinarbas]

2017'de hayatımız değişmişti. Değişmek durumunda kalmıştı.

Elimizde bir a4 kağıdı karşımızda bulutların üstüne kadar yükselmiş aşılmaz sıradağlar vardı. Yolun adı otizm. Sıra dağların adları, eğiticilerin eğitimsizliği, farkındalık yoksunluğu, iletişim kuramayan öğretmenler vb.

[NEJM @NEJM]

Presented at #EAU23: In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival (ProtecT trial) https://t.co/G2ABkMkyJg

#oncology

[JAMA Network Open @JAMANetworkOpen]

The surveillance rate for low-risk #ProstateCancer has risen from 27% to 60%, 2014-2021, but overtreatment remains common, with substantial local variation. @dr_coops @dannymak #pcsm @amerurological Quality AQUA Registry https://t.co/uMVC4oxYLc

[Emre Yekedüz @yekeduz_emre]

We have more and strong options than ADT in the treatment of mCSPC. A living meta-analysis just published @JAMAOnc
https://t.co/kVFu1qOke4

@DrYukselUrun @Silke_Gillessen @APCCC_Lugano @PCF_Science @OncoAlert

[Yüksel Ürün @DrYukselUrun]

PSMA is here, it's time to learn how to use it most effectively in the diagnosis and treatment of our patients!
@NatRevUrol @OncoAlert @APCCC_Lugano @PCF_Science @RSNA @SNM_MI @piet_ost @_ShankarSiva @DrMHofman @declangmurphy @stefanofanti4 @Uroweb
https://t.co/cqhp2o6erb

[European Urology @EUplatinum]

Incorporating PSMA PET in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer

https://t.co/52K7hr9Slq

@LauraBukavinaMD @AmyLuckenbaugh @DrMHofman @sophia_kamran @declangmurphy @KOSJ12 @piet_ost

[Scott Eggener @uroegg]

If you remain interested in the G6/GG1 'cancer vs no cancer' discussion, should be aware of this paper by mostly pathologists but also plenty of clinicians.

My/our response to their points in a thread to follow

https://t.co/Lehg1bz8hE

[Sci-Hub @sci_hub_]

November 6 🎂🥳🎉: Happy birthday and long life to Alexandra Elbakyan!

Neuroscientist and software developer #Alexandra Elbakyan who revolutionized the academic and scientific world with her ideals of open access to scientific knowledge.

[European Urology @EUplatinum]

New Platinum Priority Editorial from @VickersBiostats @dr_coops @uroegg

Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm

https://t.co/8I3lffejbk

[Andrew Vickers @VickersBiostats]

The rationale for removing the cancer designation from Gleason pattern 3 is 100% practical. What will happen if we continue to call pattern 3 cancer &amp; what will happen if, instead, we use a label other than cancer? https://t.co/q98tLUwiIj @uroegg @dr_coops

[Andrew Vickers @VickersBiostats]

Medical prediction models typically have binary endpoint &amp; give risk of cancer/death/MI etc. Any examples of prediction models with continuous endpoint? eg.amount pain relief from surgery. @f2harrell @mike__kattan @BenVanCalster @ESteyerberg @MaartenvSmeden @GSCollins

[Peter Ueda @PeterUeda1]

Assistant professor vs Editor

[Wei Shen Tan @drtanws]

#Twittorial on our recent @IBCG on risk stratifying intermediate risk NMIBC now in print in @EurUrolOncol
#bladdercancer
#MedTwitter
#UroSoMe

https://t.co/ONe03SazAW

[Hossein Taghizadeh @HosseinTaghiz11]

Dear #MedTwitter
RCC therapy is becoming increasingly complex.
Here an overview for you from the 5 pivotal trials.
Hopefully it is useful for you for your presentations and clinical decision findings.
@DrChoueiri @montypal @RenoHemonc @OncBrothers @OncoAlert @DrYukselUrun

[Yüksel Ürün @DrYukselUrun]

Is it time for neoadjuvant before radical prostatectomy?
💊💉ARNEO: Degarelix with/Without Apalutamide Prior to RP for High-risk #ProstateCancer
🔶Minimal residual disease:DA 38%🆚D 9.1%, no pCR
🔶PTEN loss lesses MRD 11%🆚43%
🔶PROTEUS trial awaited @OncoAlert @Uroweb @ASCO

[Türkiye Psikiyatri @PsikiyatriDer]

Yapılması planlanan ve bazı kurumlarca desteklenen, nefret temelli “LGBTİ+ karşıtı” yürüyüş çağrılarını kaygıyla izliyoruz. İlgili tüm kurum ve kişileri bu hatadan bir an önce dönmeye, hakikatin yanında durmaya ve sağduyuya çağırıyoruz.

[Shahrokh F. Shariat @DrShariat]

triplet combination therapy improves survival in mHSPC compared with doublet regimens. Our findings need to be confirmed in further head-to-head trials with longer follow-up https://t.co/n6NZNfPrgm